Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP4 | P55087 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379803 | 0.83 | AQP4 (0.70) | AQP4NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3178619 | 0.78 | NPC1 (0.72) | AQP4NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL7553959 | 0.76 | AQP4 (0.61) | AQP4SMN1; SMN2L3MBTL1MAPTLMNA | |
| SCHEMBL8127812 | 0.75 | AQP4 (0.60) | AQP4RAB9ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL7348856 | 0.75 | LMNA (0.62) | AQP4NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL8554147 | 0.75 | LMNA (0.65) | AQP4NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL9963857 | 0.74 | KDM4E (0.61) | AQP4NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL25287793 | 0.73 | LMNA (0.90) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL10406072 | 0.73 | KMT2A (0.66) | AQP4RAB9ASMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL1924051 | 0.73 | NPC1 (0.63) | AQP4NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137265-A1 | METHODS AND COMPOSITIONS FOR REDUCING GLIAPTOSIS: MACROGLIA-INDUCED NEURONAL CELL DEATH | SAINT MICHAEL'S COLLEGE, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025075479-A1 | USE OF AQUAPORIN 4 INHIBITOR FOR TREATING ATRIAL FIBRILLATION | 이화여자대학교 산학협력단 | 2025-04-10 | — | — | WO | claimed |
| CN-118178653-A | Application of transmembrane water-exchange protein AQP4 inhibitor in preparation of antitumor drugs | 山东第一医科大学附属省立医院(山东省立医院) | 2024-06-14 | — | — | CN | claimed |
| CN-121449682-A | Preparation method of targeted drug polypeptide for glioma treatment, product and application thereof | 国家纳米科学中心 | 2026-02-03 | — | — | CN | disclosed |
| WO-2025137265-A1 | METHODS AND COMPOSITIONS FOR REDUCING GLIAPTOSIS: MACROGLIA-INDUCED NEURONAL CELL DEATH | SAINT MICHAEL'S COLLEGE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025075479-A1 | USE OF AQUAPORIN 4 INHIBITOR FOR TREATING ATRIAL FIBRILLATION | 이화여자대학교 산학협력단 | 2025-04-10 | — | — | WO | disclosed |
| WO-2024228954-A2 | COMPOSITIONS FOR MODULATING THE EXPRESSION OF AQUAPORINS IN NEURODEGENERATIVE DISORDERS | MAJEED ANJU (IN) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024228949-A1 | COMPOSITIONS FOR MODULATING THE EXPRESSION OF AQUAPORINS IN DIABETES AND ASSOCIATED CONDITIONS | MAJEED ANJU (IN) | 2024-11-07 | — | — | WO | disclosed |
| EP-4455654-A1 | METHOD FOR MEASURING OUTFLOW RATE OF WATER MOLECULES ACROSS CELL MEMBRANES, USES OF OUTFLOW RATE OF WATER MOLECULES ACROSS CELL MEMBRANES, AND METHOD AND SYSTEM FOR MEASURING GLIOMA MAGNETIC RESONANCE IMAGING MARKERS | Zhejiang University (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240316085-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-12029733-B2 | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system | Tulavi Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-10945995-B2 | Compositions and methods for channelopathy disorders-targeting fluid movement across membranes | DEHA, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200281898-A1 | Compositions and Methods for Channelopathy Disorders-Targeting Fluid Movement Across Membranes | SRIPATHIRATHAN, Kumar | 2020-09-10 | — | — | US | disclosed |
| WO-2019067458-A1 | COMPOSITIONS AND METHODS FOR CHANNELOPATHY DISORDERS-TARGETING FLUID MOVEMENT ACROSS MEMBRANES | DEHA, LLC (US) | 2019-04-04 | — | — | WO | disclosed |
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659312-B2 | Inhibitors of Aquaporin 4, methods and uses thereof | NIIGATA UNIVERSITY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | NIIGATA UNIVERSITY (JP) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281898-A1 | Compositions and Methods for Channelopathy Disorders-Targeting Fluid Movement Across Membranes | AQP4, AQP1, AQP3 | AQP4 1/4885NPC1 238/4885RAB9A 1457/4885 |
| US-10945995-B2 | Compositions and methods for channelopathy disorders-targeting fluid movement across membranes | AQP4, AQP1, AQP3 | AQP4 1/4885NPC1 238/4885RAB9A 1457/4885 |
| US-20070281978-A1 | INHIBITORS OF AQUAPORIN 4, METHODS AND USES THEREOF | AQP4, AQP1, AQP3 | AQP4 1/4885NPC1 276/4885RAB9A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.